|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
0.85/3.84
|
企业价值
100.60M
|
资产负债 |
每股账面净值
19.45
|
现金流量 |
现金流量率
--
|
损益表 |
收益
316.61M
|
每股收益
19.88
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/06/02 06:14 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Eagle Pharmaceuticals Inc is a specialty pharmaceutical company. The company develops and commercializes injectable products in the areas of critical care, orphan diseases, and oncology. Its product portfolio consists of four approved products: Argatroban, Ryanodex, Belrapzo, and Bendeka. The company currently has multiple product candidates in advanced stages of development and is under review for approval by the Food and Drug Administration. |